NICE draft guidance recommends against Biogen's Spinraza for SMA

U.K.’s NICE published draft guidance recommending against the use of Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) to treat spinal muscular atrophy. The committee cited significant uncertainties around Spinraza's long-term benefits, as well as the drug's “extremely high” cost.

Based on Spinraza's

Read the full 408 word article

User Sign In